<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02031419</url>
  </required_header>
  <id_info>
    <org_study_id>CC-122-DLBCL-001</org_study_id>
    <nct_id>NCT02031419</nct_id>
  </id_info>
  <brief_title>Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma</brief_title>
  <official_title>A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First study, at multiple clinical centers, exploring the effects of different combinations of
      compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma
      (DLBCL) and Follicular Lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study CC-122-DLBCL-001 is a Phase 1b dose escalation and expansion clinical study of CC 122,
      CC-223 and CC-292 administered orally as doublets with or without rituximab, in subjects with
      relapsed/refractory DLBCL who have failed standard therapy.

      In expansion phase, selected combination will be administered to lenalidomide naïve FL
      subjects and lenalidomide exposed FL subjects in addition to relapsed/refractory DLBCL
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2013</start_date>
  <completion_date type="Anticipated">December 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>From the time of informed consent, throughout dosing period and for 28 days after the last dose of study drug.</time_frame>
    <description>To determine safety profiles and dose-limiting toxicities of study drug combinations using NCI CTCAE v4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Every 2-3 months until proof of tumor progression</time_frame>
    <description>Tumor response rates using Cheson Revised Response Criteria for Malignant Lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CC-223 and CC-292 interaction</measure>
    <time_frame>Day 1, Day 15</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <arm_group>
    <arm_group_label>CC-122 + CC-223 +/- rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-122 + CC-292 +/- rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-292 + CC-223 +/- rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-122 + rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-122 administered orally once daily in combination with Rituximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-122</intervention_name>
    <description>2mg or 3 mg administered orally once daily</description>
    <arm_group_label>CC-122 + CC-223 +/- rituximab</arm_group_label>
    <arm_group_label>CC-122 + rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-223</intervention_name>
    <description>20mg or 30mg administered orally once daily.</description>
    <arm_group_label>CC-122 + CC-223 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 administered intravenously once every 28 days</description>
    <arm_group_label>CC-122 + CC-223 +/- rituximab</arm_group_label>
    <arm_group_label>CC-122 + rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-122</intervention_name>
    <description>2mg or 3mg administered orally once daily.</description>
    <arm_group_label>CC-122 + CC-292 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-292</intervention_name>
    <description>500 mg twice a day administered orally.</description>
    <arm_group_label>CC-122 + CC-292 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 administered intravenously once every 28 days</description>
    <arm_group_label>CC-122 + CC-292 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-223</intervention_name>
    <description>20mg or 30mg per day administered orally daily.</description>
    <arm_group_label>CC-292 + CC-223 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-292</intervention_name>
    <description>500 mg twice a day administered orally.</description>
    <arm_group_label>CC-292 + CC-223 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 administered intravenously once every 28 days</description>
    <arm_group_label>CC-292 + CC-223 +/- rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, 18 years or older, with histologically or cytologically-confirmed
             either:

               1. Chemo-refractory DLBCL (including transformed low grade lymphoma)

               2. Lenalidomide naïve; relapsed or refractory CD20-positive follicular lymphoma
                  (Grade 1, 2, or 3a) following at least one prior standard systemic treatment
                  regimen including systemic chemo-, immune-; or chemo-immunotherapy and at least
                  one prior line of salvage therapy with no prior exposure to lenalidomide, or
                  double-refractory FL subjects with no prior exposure to lenalidomide (FL-1
                  cohort)

               3. Lenalidomide exposed: relapsed or refractory CD20-positive follicular lymphoma
                  (Grade 1, 2, or 3a) previously treated with at least two cycles of
                  lenalidomide-containing regimen (FL-2 cohort), either as a single agent or in
                  combination

          -  At least one site of measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.

          -  Subjects must have the following laboratory values:

          -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L or ≥ 1.0 x 109/L (with bone marrow
             involvement with DLBCL)

          -  Hemoglobin (Hgb) ≥ 8 g/dL.

          -  Potassium within normal limits

          -  Asparate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) and
             Alanine Aminotransferase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) ≤ 2.5 x Upper
             Limit of Normal (ULN) or ≤ 5.0 X ULN if liver tumor is present.

          -  Serum bilirubin ≤ 1.5 x ULN.

          -  Estimated serum creatinine clearance of ≥ 50 mL/min

          -  Subjects must have the following laboratory values:

        Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L without growth factor support for 7 days (14
        days if subject received pegfilgrastim).

          -  Males enrolled into treatment arms receiving CC-122 must: Agree to abstain from
             donating sperm while taking IP and for at least 3 months following discontinuation of
             IP

        Exclusion Criteria:

          -  Symptomatic central nervous system involvement.

          -  Known symptomatic acute or chronic pancreatitis.

          -  Persistent diarrhea or malabsorption despite medical management.

          -  Peripheral neuropathy ≥ grade 2

          -  Impaired cardiac function or clinically significant cardiac diseases

          -  Subjects with diabetes on active treatment (for subjects treated on CC-223 containing
             arms only)

          -  Prior autologous stem cell transplant (ASCT) ≤ 3 months before first dose.

          -  Prior allogeneic stem cell transplant with either standard or reduced intensity
             conditioning.

          -  Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives
             or 4 weeks prior to starting study drugs, whichever is shorter.

          -  Subjects who have undergone major surgery ≤ 2 weeks prior to starting study drugs.

          -  Women who are pregnant or breast feeding. Adults of reproductive potential not willing
             to employ two forms of birth control.

          -  Subjects with known HIV infection, chronic active hepatitis B or C virus (HBV/HCV)
             infection.

          -  Subjects with treatment-related myelodysplastic syndrome.

          -  History of concurrent second cancers requiring active, ongoing systemic treatment.

          -  Prior treatment with a dual mTORC1/mTORC2 inhibitor (CC-223 arms only) or BTK
             inhibitor (PCI-32765) (CC-292 arms only). [Prior treatment with rapamycin analogues,
             PI3K or AKT inhibitors, lenalidomide and rituximab are allowed].
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Pourdehnad, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sansum Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers, LLP [Boulder-COBO]</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Cencer and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University, Division of Hematology Oncology, Dept. of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401-8122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Osteoporosis Clinical Center and Research Program</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano (MI)</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedaliera San Giovanni Battista Molinette</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-122</keyword>
  <keyword>CC-223</keyword>
  <keyword>CC-292</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Lenalidomide naïve Follicular Lymphoma</keyword>
  <keyword>Lenalidomide exposed Follicular Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

